Advancing Cancer Research Through Proteogenomics and Greater Collaboration
The Josep Carreras Institute will focus its studies on leukaemia in the Spanish population, as well as on new efforts in the emerging scientific area of proteogenomics for precision oncology.
Dr. Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute, ICREA researcher and Chairman of Genetics at the University of Barcelona, and Dr. Carolina De la Torre, head of the Josep Carreras Leukaemia Research Institute proteomics facility, consider that “Our participation in this consortium will let our institute to move forward to the personalised medicine. To apply proteogenomic will help us to develop the patient’s stratification according to genomics, epigenetics and proteomics as well as biological and environmental factors that have a high influence in disease progression as well as to improve the disease understanding of drug response and resistance to therapies”.
The MOUs will further promote the adoption of Clinical Proteomic Tumor Analysis Consortium (CPTAC) standardized proteogenomic workflows and make rich proteogenomic datasets from a diversity of tumor types and populations available to the scientific community, to advance cancer research and care.
“This partnership aims to foster our shared goals for advancement of proteogenomics in precision oncology and to facilitate common research initiatives,” says Dr Henry Rodriguez, Director of the Office of Cancer Clinical Proteomics Research, NCI.
The NCI International Cancer Proteogenome Consortium (ICPC) is inspired by the Cancer Moonshot to encourage international cooperation among proteogenomic research centers. Today, the ICPC brings together multiple institutions in more than fourteen countries.